The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to encompass patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated…
The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to encompass patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated…